Influenza

Study: Intranasal influenza vaccine shows higher efficacy rate

Published in Medical Letter on the CDC and FDA, June 13th, 2004

Data were presented at the Pediatric Academic Societies' (PAS) annual meeting in San Francisco, California, from two phase III studies showing that a live, attenuated intranasal influenza vaccine had higher efficacy rates and a similar safety profile to the traditional flu shot.

The studies were conducted in children with a history of respiratory illness.

"The deaths of 143 children during the last influenza season add to the growing body of evidence that influenza represents an important cause of morbidity and mortality in the pediatric population," said Edward Connor, MD, senior vice president of clinical development and chief medical officer at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-06-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry